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Abstract
Objective—To investigate the association between self-reported endometriosis and the putative
functional promoter +331C/T single nucleotide polymorphism (SNP) and the PROGINS allele.
Design—Control subjects from ovarian cancer case-control studies participating in the
international Ovarian Cancer Association Consortium. The majority of controls are drawn from
population-based studies.
Setting—An international ovarian cancer consortium including studies from the Australia,
Europe and the United States,
Patients—5,812 White female controls, of whom 348 had endometriosis, from eight ovarian
cancer case-control studies.
Interventions—None.
Main Outcome Measures—Genotypes for the +331C/T SNP and PROGINS allele and a
history of endometriosis.
Results—The occurrence of endometriosis was reduced in women carrying one or more copies
of the +331 T allele (OR=0.65; 95% CI: 0.43–0.98, p=0.042), whereas there was no association
between the PROGINS allele and endometriosis (OR=0.94, 95% CI 0.76, 1.16).
Conclusions—Additional studies of the +331C/T variant are warranted given the current
finding and the equivocal results of previous studies. The +331 T allele has been shown to result
in a reduced PR-A to PR-B ratio and if the observed association with endometriosis is confirmed it
would suggest that this ratio is important for this disease.
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Introduction
Endometriosis affects approximately 5–10% of reproductive-age women (1) and this figure
may be substantially higher in women presenting with pelvic pain and/or infertility where
surgical intervention is often required. In addition, women with a history of endometriosis
also have an increased risk of endometrioid and clear cell ovarian cancer (2–5).
Similar to ovarian cancer, endometriosis is stimulated by estrogens and inhibited by
progesterone (6). The actions of progesterone are mediated by the progesterone receptor,
which is encoded by the PGR gene on chromosome 11q22-q23 (7). Through two promoter
and translational start sites, the PGR gene encodes the PR-A and PR-B isoforms of the
receptor. Although structurally similar, the actions of PR-A and PR-B differ: PR-B is a
transcriptional activator of progesterone target genes, whereas PR-A acts as a repressor of
PR-B (8).
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A putative functional polymorphism in the promoter region of the PGR, +331C/T
(rs10895068), creates an additional TATA box, which provides a unique transcriptional start
site that favors increased production of PR-B relative to PR-A (9). Due to increased
production of PR-B, this variant has been suggested to reduce the risk of endometriosis as
has been shown with endometrioid and clear cell ovarian cancer (10). Attia et al. (11)
reported lower levels of PR-A in endometriotic tissue compared to paired samples of eutopic
endometrium. PR-B was expressed in 17 of 18 eutopic samples, but there was no PR-B
expression in endometriotic tissue (11).
Berchuck et al. first suggested a reduced risk of endometriosis with the T allele of the +331
variant in a study of control women who were participants in a case-control study of ovarian
cancer in North Carolina (12). This reduced risk was also found in one study of deep
infiltrating endometriosis (13), but an increased risk was found in a second study (14).
Treloar and colleagues found no association with endometriosis and this variant (15).
Another putative functional variant in the PGR, PROGINS, has also shown equivocal results
with respect to an association with endometriosis. Several studies have suggested that the
variant increases susceptibility to endometriosis (16–18) while others have found no
association (13, 15, 19). A large pooled analysis of ovarian cancer risk and PROGINS
showed no overall association, but an increased risk associated with the endometrioid
subtype (10).
We present here the results of our analysis of the association between self-reported
endometriosis and the +331C/T and PROGINS variants in a pooled analysis of eight
different control populations from the U.S., Australia and Europe that are part of the Ovarian
Cancer Association Consortium (OCAC).
Materials and Methods
Study Populations
Seven population-based and one clinic-based (MAYO) ovarian cancer case-control studies
contributed to this analysis. The groups contributing data include the Australian Cancer
Study and the Australian Ovarian Cancer Study (AUS), the western Washington State
Ovarian Cancer Case-Control Study (DOVE), the Hormones and Ovarian Cancer Prediction
Study of Delaware Valley (HOPE), the Danish Malignant Ovarian Cancer Study
(MALOVA), the Mayo Clinic Ovarian Cancer Case-Control Study (MAYO), the North
Carolina Ovarian Cancer Study (NCOCS), the New England-based Case-Control Study
(NECC), and the Los Angeles County Case-Control Studies of Ovarian Cancer (USC). The
original report on +331 and endometriosis from Berchuck and colleagues (12) included a
smaller subset of subjects from the NCOCS than those used in the current study. The results
presented here are limited to the White control subjects from these studies.
Details of these studies, including methods of control ascertainment, data collection and
participation rates, are provided in Table 1 and have been described previously (10, 20, 21).
Data collection included information regarding menstrual, reproductive, and gynecologic
histories; birth control and hormone use; and lifestyle factors. Endometriosis was self-
reported. In addition, blood or saliva samples were collected for DNA extraction. These are
the same studies we previously evaluated for association with ovarian cancer risk described
in a study by Pearce et al. (10), but with the CONN, FROC, POCS and SEARCH studies
excluded from the current analysis because they did not have data on endometriosis.
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Genotyping and Quality Control
The two PGR SNPs genotyped for this analysis were +331C/T (rs10895068) and PROGINS
(rs1042838). The PROGINS allele was measured by the exon 4 missense SNP (rs1042838)
which is in perfect linkage disequilibrium with the ALU insertion first used to define the
PROGINS allele. Allele designations were based on the forward strand as given in the
University of California at Santa Cruz (UCSC) genome browser (10). DOVE, HOPE,
MALOVA, NCOCS, NECC and USC used the 5′ nuclease Taqman allelic discrimination
assay (Applied Biosystems, Foster City, CA) for genotyping. ACS and AOCS used the iPlex
Sequenom MassArray system (Sequenom Inc., San Diego, CA) and MAYO used
Pyrosequencing for genotyping. Laboratory to laboratory quality control was assessed by
genotyping a common set of 90 DNAs that showed greater than 99% concordance.
Concordance between duplicate samples in each individual study was >98% for both SNPs.
Hardy-Weinberg equilibrium (HWE) for the two polymorphisms was confirmed among
White controls for each study using the χ2 goodness-of-fit test (Table 1).
Statistical Analysis
Endometriosis was a dichotomous outcome (yes/no). MALOVA data were included even
though the prevalence of endometriosis in controls was very low (1.0%) because the
investigators found that after reviewing their data collection procedures they had no reason
to doubt this variable would not accurately reflect the reports of the study subjects. The
results of analyses conducted with and without the MALOVA study were similar.
Endometriosis rates for the other seven studies were in line with expectations.
Unconditional logistic regression was used to evaluate the association between
endometriosis (outcome) and genotype. All analyses were stratified on study and age (<40,
40–49, 50–59, 60–69, 70+). A log additive genetic model was used for the PROGINS
variant as there was no a priori reason to believe this variant acts under a different model.
Odds ratios (ORs) and 95% confidence intervals (CIs) are expressed per copy of the minor
allele carried for PROGINS. For +331C/T, the minor allele frequency was only 6%,
therefore this SNP was modeled using a dichotomous variable and all ORs and 95% CIs for
this variant depict associations for heterozygotes and rare homozygotes combined compared
to common homozygotes (i.e., dominant genetic model). All statistical significance levels
(p-values) quoted are two-sided. Heterogeneity by study site was evaluated by the likelihood
ratio (LR) test comparing models with and without cross-product terms representing study
site and genotype. Analyses were conducted using SAS (Version 9.1, SAS Institute, Cary,
NC).
Approval and Consent
All participants provided written informed consent prior to the interview and collection of
biological samples. The University of Southern California and Duke University obtained
institutional review board (IRB) approval to serve as data coordinating centers for the
OCAC. The authors also obtained approval from the University of Michigan Institution
Review Board as some analyses were conducted there as well. The investigators have no
conflicts of interest to disclose.
Results
A total of 5,812 women who had served as controls for one of the ovarian cancer case-
control studies were available for this analysis; their mean age was 55.5 years (standard
deviation 11.9; range 16–91). The prevalence of endometriosis was 6.0% overall (n=348);
the prevalence was between 5% and 8% in seven of the eight studies. The overall minor
allele frequencies (MAFs) for +331C/T and PROGINS by study are shown in Table 1.
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We found borderline evidence that endometriosis was associated with carrying one or two
copies of the +331 T allele (OR = 0.65, 95% CI = 0.43–0.98, p=0.042; Table 2). This
association showed no evidence of heterogeneity of effect by study (phet = 0.53). Given the
low prevalence of endometriosis in the MALOVA study, we excluded these data from the
analysis and the results were unchanged (data not shown). After excluding the data from
NCOCS that appeared in the initial report from Berchuck and colleagues (12), an inverse
association was still observed (OR=0.72, 95% CI 0.47, 1.17), but the result was no longer
statistically significant (p=0.13). The individual study ORs and 95% CIs are given in Figure
1.
The association observed between endometriosis and the PROGINS allele was small and did
not reach statistical significance (OR = 0.94 per copy of the minor allele, 95% CI = 0.76–
1.16, p=0.56; Table 2). No evidence of heterogeneity of effect by study center was observed
(phet = 0.12).
Discussion
We observed a 35% reduction in the presence of endometriosis among carriers of the +331 T
allele (95% CI 2%–57%). The +331C/T has been shown to influence the transcription of
PR-B relative to PR-A with the T allele favoring PR-B (9). PR-B acts as a classic hormone
receptor, mediating the effects of progesterone whereas PR-A acts as a repressor of PR-B
and as a result, the presence of the +331 T allele is hypothesized to lead to a greater effect of
progesterone. Our finding of a reduced risk is biologically plausible since endometriosis is
responsive to progesterone.
Attia and colleagues also showed lower levels of PR-B in endometriotic lesions (11) which
would be consistent with a protective role of a variant that increased PR-B and therefore
progesterone responsiveness. Also, an association between the +331C/T variant and ovarian
cancer was observed with both clear cell and endometrioid ovarian cancers, but not the other
histological subtypes (OR=0.81, p=0.058) (10).
The existing literature on the +331 T allele is contradictory. After Berchuck and colleagues
(12) first suggested a reduced risk of endometriosis associated with the T allele of the +331
variant, Treloar et al. (15) conducted a large study which included more than 900 families
(child-parent trios) and found no association. Van Kaam and colleagues (13) reported a 33%
decreased risk for deep infiltrating endometriosis in women who carry the +331 T allele
(13), but this is in the opposite direction from that reported by Gentilini et al (14). However,
both the studies of van Kaam et al. and Gentilini et al. were hospital-based and utilized
controls with gynecological conditions and those referred for genetic testing so it is possible
that the differences found were due to inadequate control selection. Also, both studies were
small, with less than 100 and 200 cases, respectively. Furthermore, the CT and TT combined
genotype frequencies reported for the general White control populations (those referred for
genetic testing) by van Kaam et al. (18.3%) (13) and Gentilini et al. (4.3%) (14) are high and
low, respectively, compared to that found in the eight White populations included in our
study (8%–14%), including the European MALOVA study (14%). This difference in
genotype frequencies may account for the difference in findings between these two studies.
Also, genotyping quality control measures are not adequately described for either the van
Kaam et al. or Gentilini et al. studies (13, 14). All of these design issues make the results of
these two studies difficult to interpret. However, the null study from Treloar and colleagues
for which all women with endometriosis were surgically confirmed does not suffer from
such design issues (15), leaving open the possibility that our finding is due to chance,
particularly given the borderline statistically significant p-value that we observed (p=0.042).
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Further research is warranted to clarify the role of the +331 variant in the development of
endometriosis.
There was no association between the PROGINS allele and risk of endometriosis (p=0.56).
While these findings fail to support three previous studies which suggested an increase in
susceptibility to endometriosis in women carrying the PROGINS allele (16–18), they are in
accordance with the results found by Treloar et al. (15), van Kaam et al. (13) and Govindan
et al. (19). The observation of no association may not be surprising given that the association
between the PROGINS and ovarian cancer risk was observed with endometrioid ovarian
cancer, but not the clear cell subtype.
This study was conducted among controls from a set of eight ovarian cancer case-control
studies. The prevalence of endometriosis reported among control women is compatible with
most population estimates of endometriosis (1) and our study is large compared with most
other reports in the literature. The controls appear representative of women in the areas
where these studies were conducted. Importantly, there was also no evidence of
heterogeneity among the eight studies pooled for this analysis supporting the validity of the
findings.
All of the endometriosis data are based on self-report of a physician diagnosis. There is
undoubtedly some misclassification of endometriosis diagnosis among affected individuals
given that the condition was not necessarily surgically confirmed. Similarly, it is possible
that women who reported no endometriosis could have the disease, but not have been
diagnosed or informed of this diagnosis by their physician. The major limitation of this
study is the small number of women with endometriosis (n=348) which restricts the
statistical power to detect associations at very stringent levels of significance. The number
of OCAC members is growing and represent a powerful forum in which to conduct genetic
association studies as well as to explore in more detail the association between ovarian
cancer risk and endometriosis. Extensive questionnaire data are available from many of the
OCAC studies which allows for the evaluation of other factors such as oral contraceptive
use. Additionally, we are able to examine the role of ovarian cancer histological subtype
associated with endometriosis in this collaborative effort. Such studies are underway.
We have provided suggestive evidence for a role of variation in the PGR gene with
endometriosis. The clinical implications of this finding are not clear at this point, but our
results indicate that progesterone signaling may be important in this disease. Additional
follow-up is warranted to further examine this relationship with endometriosis and the +331
variant as well as to explore the potential synergistic relationship between endometriosis,
PGR variation and ovarian cancer risk.
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Figure 1.
Forrest plot of the association between the +331 T allele and risk of endometriosis for the
eight included studies. The summary odds ratio is 0.65 (95% CI 0.43, 0.98, p=0.042).
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